The promises (“aggressive action”, “significant increases in funding”) have been heartening but the proof, as they say, is in the pudding. We got our first taste of what the NIH has in store for ME/CFS recently. The taste, however, was not so sweet.
ME & Long COVID patients need telemedicine prescribing flexibility
DEA should amend its proposed rule to ensure access to care